Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Yes. A licensed clinician can prescribe a GLP-1 medication through telehealth if you meet eligibility criteria, often BMI 30 or BMI 27 with a weight-related condition. After a virtual medical review, the clinician may prescribe an FDA-approved branded option or, when appropriate, a compounded GLP-1 for home delivery.[1][2][3]
Can a virtual doctor really prescribe a GLP-1?
Online GLP-1 prescription visits are real medical visits. A virtual clinician can prescribe when the clinician is licensed where care is delivered, state rules are met, and the patient’s health profile supports treatment. GLP-1 medicines are prescription drugs, so they require a valid prescription and clinical oversight.[1][2][6]
A good telehealth visit should not be a quick checkout page. The clinician should review possible benefits seen in clinical trials, plus common risks such as nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder problems, pancreatitis warnings, and boxed warnings for thyroid C-cell tumors on several GLP-1 and GIP/GLP-1 labels.[1][2][10][11]
You should not expect to get Ozempic, Wegovy, Zepbound, compounded semaglutide, or compounded tirzepatide without a medical review. A provider that skips safety questions, promises approval, or guarantees a specific weight-loss result is not following careful medical care. Individual results vary in trials and in practice.[10][11]
Which GLP-1 medications can be prescribed online?
GLP-1 medications include FDA-approved weight-management drugs, FDA-approved diabetes drugs, investigational oral agents, and compounded versions. Their FDA status is not the same, so the online visit should make clear which option is being discussed and what risks apply.[1][2][4][5][8]
Branded injectables: Wegovy, Zepbound, and Saxenda
Wegovy (semaglutide, a GLP-1 receptor agonist; semaglutide may also be available as a compounded formulation through licensed 503A pharmacies) is FDA-approved for chronic weight management in certain adults and adolescents. The FDA-approved Wegovy label lists 0.25 mg once weekly as the initial dose for weeks 1 through 4, with a maintenance dose of 2.4 mg once weekly for most adults; the same label lists common side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dyspepsia.[1]
Zepbound (tirzepatide, a GIP/GLP-1 dual agonist; tirzepatide may also be available as a compounded formulation through licensed 503A pharmacies) is FDA-approved for chronic weight management in certain adults. The FDA-approved Zepbound label lists 2.5 mg once weekly as the initiation dose for 4 weeks and maintenance doses of 5 mg, 10 mg, or 15 mg once weekly; the label also lists common side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and gastroesophageal reflux disease.[2]
Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in certain adults and pediatric patients. The FDA-approved Saxenda label describes a once-daily injection schedule that escalates from 0.6 mg to 3 mg, and it lists warnings for thyroid C-cell tumors, pancreatitis, gallbladder disease, hypoglycemia risk with some diabetes medicines, increased heart rate, kidney injury, and suicidal behavior or thinking.[3]
Branded oral GLP-1s: oral semaglutide and orforglipron
Rybelsus (oral semaglutide, a GLP-1 receptor agonist) is FDA-approved for adults with type 2 diabetes, not chronic weight management. The FDA-approved Rybelsus label lists 3 mg once daily for 30 days as an initial dose, followed by higher labeled diabetes doses, and it includes gastrointestinal side effects and the thyroid C-cell tumor boxed warning.[6]
Oral semaglutide has also been studied for weight management. In the OASIS 1 trial, adults with overweight or obesity received once-daily oral semaglutide 50 mg or placebo, and the study reported greater weight loss with semaglutide along with more gastrointestinal adverse events; individual results vary.[12]
Orforglipron (an oral non-peptide GLP-1 receptor agonist sometimes searched with the brand term Foundayo) has been studied for obesity and type 2 diabetes, but it should be treated as investigational for weight management unless an FDA-approved label is available. In a phase 2 obesity trial, participants received oral orforglipron doses ranging from 12 mg to 45 mg once daily, and gastrointestinal events were the most common adverse events.[13]
Compounded semaglutide and compounded tirzepatide via 503A pharmacies
Compounded semaglutide via a 503A pharmacy and compounded tirzepatide via a 503A pharmacy are custom-prepared medications for individual patients when clinically appropriate. Compounded medications are not FDA-approved products, and FDA has warned about dosing errors, ingredient concerns, and adverse events reported with compounded semaglutide and tirzepatide products.[8][9]
A state-licensed 503A compounding pharmacy prepares medication based on a patient-specific prescription. This is different from an FDA-approved manufacturer making a branded product under an FDA-approved label. Patients should ask where the medication is compounded, whether the pharmacy is licensed, and how sterility and potency are checked.[8][9]
Who is eligible for an online GLP-1 prescription?
GLP-1 eligibility usually starts with BMI and health history. FDA weight-management labels commonly include adults with BMI 30 kg/m² or higher, or BMI 27 kg/m² or higher with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or dyslipidemia.[1][2][3]
BMI and health-condition thresholds
BMI is a screening tool, not a full diagnosis. A clinician may also review waist size, blood pressure, A1C or glucose history, cholesterol, sleep apnea, liver health, current medicines, prior weight-loss treatment, and eating-disorder history. Expected benefits should be balanced with side effects and long-term follow-up needs.[1][2][10][11]
Who should not take a GLP-1
Wegovy, Zepbound, and Saxenda carry a boxed warning about thyroid C-cell tumors. These labels state that the drugs are contraindicated for people with a personal or family history of medullary thyroid carcinoma, called MTC, or multiple endocrine neoplasia syndrome type 2, called MEN 2.[1][2][3]
Pregnancy is another key safety issue. Weight-loss medications are generally not used during pregnancy, and FDA labels include pregnancy-related warnings or recommendations to stop use when pregnancy is recognized. A clinician should also review pancreatitis history, gallbladder disease, kidney problems, severe gastrointestinal disease, diabetes medicines, allergies, and mental health history where relevant.[1][2][3]
How does an online GLP-1 visit actually work?
An online GLP-1 visit should include intake, identity and location checks, clinician review, a prescription decision, pharmacy coordination, and follow-up. Many visits can be completed from home, but a clinician may still request labs, records, or in-person care if a safety concern comes up.[1][2][7]
Intake and health history
The intake usually asks about height, weight, BMI, weight-related conditions, current medicines, allergies, pregnancy plans, past pancreatitis, gallbladder disease, thyroid cancer history, MEN 2, diabetes, and prior weight-loss treatments. This helps the clinician weigh likely benefit against known risks before prescribing.[1][2][3]
Clinician review and prescription
If you appear eligible, the clinician may discuss FDA-approved branded options, insurance steps, or compounded GLP-1 options when appropriate. The clinician should explain common side effects, such as nausea, vomiting, diarrhea, constipation, and abdominal pain, and review red-flag symptoms that need medical attention.[1][2][8]
Home delivery and follow-up
If a prescription is issued, the pharmacy may ship medication to your home with storage instructions and injection supplies when needed. Follow-up matters because dose decisions, side effects, missed doses, pregnancy plans, blood sugar changes, and weight response need clinical review over time.[1][2][3]
3-min quiz
Have questions before starting?
A licensed clinician can review your history, eligibility, medication options, and safety concerns before any prescription decision is made.
What does an online GLP-1 prescription cost?
GLP-1 cost depends on the medication, insurance coverage, pharmacy, visit fees, labs, shipping, and follow-up. Branded GLP-1 list prices are often in the $1,000-plus per month range before insurance or savings programs, while compounded GLP-1 pricing is usually cash-pay and varies by provider and pharmacy.[14][15]
Insurance-covered branded GLP-1s
Insurance may cover Wegovy, Zepbound, or Saxenda when the plan includes weight-management drugs and the patient meets criteria. Plans may require prior authorization, proof of BMI, documentation of weight-related conditions, step therapy, or ongoing response checks. Coverage does not remove the need to review side effects and contraindications.[1][2][3]
Cash-pay branded pricing
Cash-pay branded GLP-1 medications can be expensive, and manufacturer savings programs may have limits. Patients should confirm medication cost, pharmacy availability, visit fees, labs, shipping, and what follow-up is included before starting, because ongoing monitoring is part of safer use.[14][15]
Compounded GLP-1 pricing
Compounded GLP-1 pricing is often listed as a monthly cash-pay amount, but patients should look beyond price. Ask whether the medication comes from a licensed 503A pharmacy, whether the prescription is patient-specific, how quality is tested, what support is included, and how side effects are handled.[8][9]
Branded vs. compounded GLP-1s prescribed online
Branded and compounded GLP-1s can both come up in telehealth care, but they are not the same. The key difference is FDA approval status: branded drugs have FDA-approved labels, while compounded drugs are not FDA-approved and are prepared for individual patients under pharmacy compounding rules.[1][2][8]
| Option | FDA status | Common online path | Potential advantages | Key safety limits |
|---|---|---|---|---|
| Wegovy (semaglutide) | FDA-approved for chronic weight management in certain patients | Telehealth evaluation, prior authorization if insured, retail or mail-order pharmacy | FDA-approved label; trial evidence for weight loss and cardiovascular-risk reduction in certain patients | Boxed warning for thyroid C-cell tumors; GI side effects; contraindicated with MTC or MEN 2 history |
| Zepbound (tirzepatide) | FDA-approved for chronic weight management in certain adults | Telehealth evaluation, insurance or cash-pay pharmacy pathway | FDA-approved label; trial evidence for weight reduction | Boxed warning for thyroid C-cell tumors; GI side effects; contraindicated with MTC or MEN 2 history |
| Saxenda (liraglutide) | FDA-approved for chronic weight management in certain adults and pediatric patients | Telehealth evaluation and pharmacy fulfillment | FDA-approved label; longer history of clinical use | Boxed warning for thyroid C-cell tumors; GI side effects; daily injection schedule on label |
| Ozempic or Mounjaro | FDA-approved for type 2 diabetes, not weight loss | May be discussed when diabetes is part of the health picture | FDA-approved diabetes labels; weight change may occur in some patients | Weight-loss use is off-label; same safety screening is needed |
| Compounded semaglutide or compounded tirzepatide | Not FDA-approved products | Clinician prescription sent to an appropriate compounding pharmacy | May be an option when clinically appropriate and legally available for an individual patient | FDA warns about quality, ingredient, dosing-error, and adverse-event risks; pharmacy vetting matters |
How do you choose a legitimate online GLP-1 provider?
A legitimate online GLP-1 provider should act like a medical clinic, not a checkout page. It should verify your identity, confirm where care is delivered, collect a real health history, explain FDA-approved and compounded options clearly, review side effects and contraindications, and offer follow-up care.[1][2][7][8]
- Look for licensed clinicians who can prescribe in your state.
- Expect questions about BMI, health conditions, medicines, allergies, pregnancy, thyroid cancer history, MEN 2, pancreatitis, gallbladder disease, and diabetes.
- Avoid any site that says you are guaranteed to qualify or guaranteed to lose a specific amount of weight. Individual results vary.
- Ask whether branded prescriptions go to a licensed pharmacy and whether compounded prescriptions go to an appropriate compounding pharmacy.
- Ask what happens if you have side effects, need a medication change, become pregnant, or stop responding.
- Check whether visit fees, medication costs, labs, shipping, refills, and follow-up are included or billed separately.
Good care includes saying no when a GLP-1 is not safe or not the right fit. That can feel frustrating, but it protects patients from avoidable risks, especially with contraindications like MTC or MEN 2 and warnings for pancreatitis, gallbladder disease, kidney injury, and severe gastrointestinal symptoms.[1][2][3]
How can you get started with an online GLP-1 evaluation?
If you are considering online GLP-1 care, you can compare licensed telehealth providers, your primary-care clinician, local obesity-medicine clinics, and Chia as one option for clinician-reviewed access to compounded GLP-1 medications through licensed 503A pharmacy partners. The right path should include eligibility screening, safety review, clear pricing, and follow-up rather than a prescription-only transaction.[1][2][8]
Before your visit, gather your height, recent weight, medication list, allergies, medical history, recent labs if you have them, and insurance details if you want to try branded coverage. Be ready to discuss goals and limits, including side effects, cost, storage, follow-up, and what to do if the medicine is not a fit.[1][2][3]
Frequently asked questions
You can complete many GLP-1 evaluations online, but you still need a licensed clinician review. A valid prescription should not be issued without screening for eligibility, side effects, contraindications, and medication interactions.[1][2]
Ozempic is FDA-approved for adults with type 2 diabetes, not for weight loss. Any weight-loss use would be off-label and should be discussed with a licensed clinician, including risks such as gastrointestinal side effects and the boxed warning about thyroid C-cell tumors.[4]
For FDA-approved weight-management GLP-1 labels, common adult thresholds are BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. A clinician must still review your full health history before deciding whether treatment is appropriate.[1][2][3]
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved products. They may be prepared for individual patients by appropriate compounding pharmacies when clinically appropriate, but FDA warns that compounded GLP-1 products can carry quality, ingredient, dosing-error, and adverse-event risks.[8][9]
The intake itself may be short, but timing depends on the provider, whether labs or records are needed, insurance prior authorization, pharmacy processing, and shipping. A careful review is more important than speed because safety screening is required.[1][2]
Yes. AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides eligibility, medication choice, and whether prescribing is appropriate.
3-min quiz
Ready to learn about your options?
A clinician-led evaluation can help you understand whether a branded or compounded GLP-1 option may be appropriate for your health history.
References
- 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2023.
- 3.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information, 2023.
- 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2025.
- 5.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2024.
- 6.U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets prescribing information, 2024.
- 7.Federation of State Medical Boards. The Appropriate Use of Telemedicine Technologies in the Practice of Medicine, 2022.
- 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
- 9.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, 2025.
- 10.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
- 11.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
- 12.Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 2023.
- 13.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 2023.
- 14.Novo Nordisk. Wegovy price and insurance information, 2026.
- 15.Eli Lilly and Company. Zepbound price and savings information, 2026.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
